Craniorachischisis Totalis

During normal development, the neural plate folds and fuses along the mid-line in a zipper-like fashion. Failure of closure at both the cranial (rostral) and caudal neuropores produces craniorachischisis. Genetic? predisposition, environmental triggers and micronutrient deficiencies disrupt cell proliferation, hinge-point formation and folate-dependent methylation reactions that power this fusion process. jcimcr.orgpmc.ncbi.nlm.nih.gov

Craniorachischisis totalis is the most catastrophic form of neural-tube defect (NTD). Because the tube fails to close from the base of the skull? to the tailbone?, the infant is born without a functional brain vault (anencephaly) and with the entire spinal cord? exposed. The condition is uniformly fatal shortly before or after birth. In practice, “treatment” is aimed at (a) preventing the defect during future pregnancies, (b) supporting the mother’s physical and emotional health, and (c) advancing research into in-utero repair that might one day rescue very early cases. pmc.ncbi.nlm.nih.govorpha.netjcimcr.org

Epidemiologically, the condition is exceedingly rare—roughly 0.1 to 0.7 per 10 000 pregnancies—but accounts for a disproportionate share of fetal and perinatal mortality linked to NTDs. No post-natal therapy can reverse the lesion?, so public-health focus centres on primary prevention, early prenatal? detection and compassionate counselling. archive.cdc.gov

Types

Although “craniorachischisis totalis” is often used as a single entity, clinicians and researchers recognise several descriptive sub-groups that help with counselling and surveillance?:

1. Total craniorachischisis – the classic picture in which the skull, cervical?, thoracic?, lumbar? and sacral arches are all missing.

2. Partial or segmental craniorachischisis – rare instances where the skull vault is absent but the spinal defect stops above the lumbosacral junction; outcome remains uniformly lethal.

3. Syndromic craniorachischisis – cases accompanied by limb-body-wall complex, sirenomelia, clefting, or visceral herniations, implying an underlying genetic or early teratogenic insult. journals.lww.comonlinelibrary.wiley.com

4. Chromosomal-associated craniorachischisis – linked to trisomy 18, triploidy or other aneuploidies; the NTD is one component of a multi-system pattern. archive.cdc.gov

Evidence-Based Causes (Risk Factors)

1. Folate deficiency – inadequate periconceptional folic-acid intake remains the single most reproducible risk. Supplementation with 4 mg/day cuts NTD recurrence? about three-fold. pmc.ncbi.nlm.nih.gov

2. Loss-of-function variants in folate-pathway genes (e.g., MTHFR, MTRR) impair one-carbon metabolism required for neural-tube closure. jcimcr.org

3. Maternal type 1 or pre-gestational diabetes? induces oxidative stress and disrupts embryonic signalling pathways. jcimcr.org

4. Maternal obesity (BMI ≥ 30) roughly doubles NTD risk, possibly via insulin resistance? and low-grade inflammation?. sciencedirect.com

5. Maternal hyperthermia or high fever? during the first six weeks can denature proteins crucial for neurulation. pubmed.ncbi.nlm.nih.gov

6. Valproic acid exposure – this anti-epileptic drug blocks HDAC enzymes and interferes with neural-fold biomechanics, producing exencephaly and craniorachischisis in up to 1–2 % of exposed pregnancies. sciencedirect.com

7. Carbamazepine and other older anti-seizure? drugs that share folate-antagonist properties.

8. Lithium therapy for bipolar disorder has been tied to increased NTD reports in large registries. sciencedirect.com

9. Anti-folate chemotherapeutics (e.g., methotrexate) administered around conception.

10. Isotretinoin – a vitamin-A derivative that disrupts neural-crest development.

11. Chronic? maternal alcohol misuse, which depletes B-vitamins and generates free radicals.

12. Maternal cigarette smoking, linked to hypoxia? and vascular compromise in the embryo.

13. Vitamin B-12 and zinc deficiency, both critical cofactors in DNA synthesis.

14. Organophosphate pesticide exposure in agricultural settings.

15. Residence at very high altitude, where chronic hypoxia alters folate transport.

16. First-trimester rubella or other viral? infections with high fever and cytokine storm. researchgate.net

17. Consanguineous marriage, which increases homozygosity for recessive alleles regulating neurulation. jcimcr.org

18. Chromosomal aneuploidy (e.g., trisomy 18), where multiple genes governing closure are dosage?-imbalanced. archive.cdc.gov

19. Severe? maternal psychosocial stress with elevated cortisol and reactive oxygen species.

20. Idiopathic? multifactorial? interaction, wherein subtle genetic variants meet mild? environmental stressors that would be harmless in isolation.

Observable Symptoms and Signs

Because craniorachischisis is usually spotted during routine scans, “symptoms” largely refer to prenatal imaging findings and newborn physical signs:

1. Absent cranial vault on ultrasound?, giving a “Mickey-Mouse” sign by 11 weeks. pmc.ncbi.nlm.nih.gov

2. Exposed, disorganised brain tissue floating in amniotic fluid?.

3. Continuous open spinal groove visible along the fetus.

4. Frog-eye facies where bulging orbits protrude.

5. Absent scalp and skin over defect, leaving a red, gelatinous surface.

6. Polyhydramnios due to impaired fetal swallowing.

7. Decreased fetal movements, reflecting severe neuro-motor impairment.

8. Fixed limb contractures (arthrogryposis) from denervation.

9. Clubfeet or rocker-bottom feet secondary to immobilisation.

10. Possible hydrocephalus if partial closure creates CSF blockage.

11. Cleft lip and palate in syndromic cases. archive.cdc.gov

12. Omphalocele or abdominal-wall defects, signalling broader mesodermal disruption.

13. Severe kyphoscoliosis because vertebral arches fail to stabilise the axis.

14. Profound hypotonia in liveborn infants.

15. Respiratory insufficiency, as brain-stem nuclei are absent.

16. Recurrent apneic spells leading rapidly to demise.

17. Hypothermia – exposed neural tissue loses heat rapidly.

18. High infection risk at the raw neural surface.

19. Stillbirth or early neonatal death, almost universal.

20. Maternal psychological distress upon diagnosis.

Diagnostic Tests

Below, tests are grouped exactly as requested. Each paragraph begins with the test name and then gives its plain-language purpose, process and what a positive finding means.

Physical-Examination Tests

1. First-trimester abdominal palpation (Leopold manoeuvres): experienced clinicians may notice the absence of normal skull hardness when the fetal head is near the fundus; this prompts urgent imaging.

2. Newborn cranial inspection: at delivery, the midwife or doctor visually confirms that the skull bones and scalp are missing, sealing the diagnosis.

3. Spinal-column inspection: running a sterile fingers’ edge along the back reveals a wide open groove instead of vertebral arches.

4. Head-circumference measurement: tape placed above the ears records an extremely low or unmeasurable circumference, denoting anencephaly.

5. Limb-tone assessment: passive flexion-extension shows little to no resistance, indicating denervation.

6. Reflex testing: Moro and grasp reflexes are absent, confirming profound neurological loss.

7. Skin-integrity check around the lesion looks for granulating tissue and risk of infection.

8. Vital-sign trending in rare livebirths detects bradycardia and apnea that presage imminent death.

Manual Tests

9. Gentle skull-rim palpation searches for any residual parietal bone; none is present in classic cases.

10. Cervical-spine flexion test gauges mechanical stability; the head flops freely because supportive arches are absent.

11. Passive limb range-of-motion documents contractures that reflect chronic in-utero paralysis.

12. Heel-to-ear manoeuvre (neonatal flexibility check) shows abnormally rigid joints.

13. Abdominal-wall palpation screens for omphalocele or herniation.

14. Hip-stability (Barlow/Ortolani) test—dislocations are common when muscle tone is lost.

15. Digital rectal tone assessment reveals flaccid sphincters indicating total spinal-cord failure.

16. Palpation for ventricular bulging at the base of exposed brain tissue may hint at trapped cerebrospinal fluid.

Laboratory and Pathological Tests

17. Maternal serum alpha-fetoprotein (AFP): levels more than 2½ times the median at 15–18 weeks strongly suggest an open NTD. archive.cdc.gov

18. Triple-screen (AFP, hCG, unconjugated estriol) improves predictive value over AFP alone.

19. Quadruple-screen adds inhibin-A for even better sensitivity.

20. Amniotic-fluid AFP via amniocentesis confirms that the protein is leaking directly from exposed fetal tissue.

21. Amniotic-fluid acetylcholinesterase assay: elevated enzyme almost pathognomonic for open NTDs.

22. Fetal karyotyping or microarray detects aneuploidy–associated craniorachischisis. archive.cdc.gov

23. Maternal red-cell folate/B-12 levels help identify modifiable deficiency.

24. Post-mortem histopathology of neural tissue shows undifferentiated neuro-epithelium with gliotic degeneration.

Electrodiagnostic Tests

25. Continuous electronic fetal heart-rate monitoring (CTG) may show non-reassuring tracings due to brain-stem loss.

26. Fetal electrocardiography records low-amplitude signals; technical success is limited but attempted in research settings.

27. Fetal magnetoencephalography (fMEG) often fails to detect organised cortical activity, validating the anatomical loss.

28. Neonatal electroencephalography (EEG) immediately after birth shows isoelectric or chaotic low-voltage patterns, confirming absent cerebral function.

29. Brainstem auditory evoked potentials (BAEPs) are absent, indicating no functional auditory pathway.

30. Somatosensory evoked potentials likewise demonstrate no conduction beyond peripheral nerves.

31. Needle electromyography (EMG) of limb muscles shows no voluntary motor unit firing, reflecting complete spinal-cord disruption.

32. Peripheral nerve-conduction studies may record preserved distal nerve action potentials, illustrating the lesion is central not peripheral.

Imaging Tests

33. First-trimester transvaginal ultrasound (11–13 weeks) is the gold-standard screening modality; the sonographer observes absent cranial bones and contiguous open spinal cord. pubmed.ncbi.nlm.nih.gov

34. Second-trimester detailed anomaly ultrasound characterises the full vertical extent of rachischisis and looks for associated defects.

35. 3-D or 4-D ultrasound provides surface rendering that aids parental counselling by clarifying severity.

36. Fetal MRI (after 18 weeks) delineates soft-tissue detail, confirms brain absence and detects co-existing thoraco-abdominal anomalies. radiopaedia.org

37. Low-dose CT (rare, post-termination) offers rapid skeletal overview when MRI is unavailable.

38. Plain radiography of the fetus/newborn shows “empty” cranial shadow and unfused neural arches.

39. Post-mortem CT or MRI (virtopsy) can substitute for conventional autopsy where cultural or religious norms preclude dissection.

40. Colour Doppler ultrasound examines large vessels for sirenomelia or limb-body-wall-complex associations.

Non-Pharmacological Interventions

Even though no post-natal cure exists, health teams still mobilise a wide range of non-drug measures to improve maternal-fetal care, inform future pregnancy planning, and—where partial variants survive—mitigate secondary complications.

A. Maternal Physiotherapy, Electro-therapy & Exercise

1. Gentle Prenatal Yoga. Purpose: ease lower-back strain and improve maternal circulation. Mechanism: slow stretching stimulates parasympathetic tone, lowering cortisol that can worsen insulin resistance.

2. Pelvic-tilt Exercises. Helps strengthen core muscles, supporting uterine weight and reducing pain that otherwise restricts mobility.

3. Prenatal Aquatic Therapy. Buoyancy unloads joints while maintaining cardiovascular fitness, indirectly improving glucose control—an NTD risk modifier.

4. Low-frequency TENS for Lumbar Pain. Safe surface electrodes reduce nociceptive signalling, letting expectant parents maintain activity.

5. Breath-focused Pilates. Trains diaphragmatic breathing, enhancing oxygenation for fetus; also moderates sympathetic spikes.

6. Manual Lymphatic Drainage. Light, rhythmical strokes clear lower-limb oedema, improving venous return and comfort.

7. Kinesio-taping Over SI Joints. Elastic tape supports lax ligaments, encouraging upright posture and fuller lung expansion.

8. Swiss-ball Sitting. Promotes pelvic alignment, minimising nerve compression pain that could otherwise necessitate opioids.

9. Prenatal Resistance-band Work. Maintains insulin sensitivity—important because maternal diabetes triples NTD risk.

10. Thermotherapy (Warm-water Baths). Local vasodilation eases myofascial tightness without systemic drug exposure.

11. Cryotherapy Packs for Sciatica. Short cold bouts blunt C-fiber transmission, providing drug-free relief.

12. Foam-roller Myofascial Release. Breaks up trigger points, prolonging exercise tolerance.

13. Physiotherapist-guided Postural Education. Correct lifting mechanics to prevent acute back injury late in gestation.

14. Biofeedback for Pelvic Floor-Relaxation. Trains appropriate muscle release, which later eases labour or surgical delivery.

15. Graduated Walking Programs. Moderate aerobic exercise optimises folate transport and endothelial health.

B. Mind-Body / Educational Self-Management

16. Periconception Health-Literacy Classes. Teach folate timing (0.4–4 mg daily at least one month before conception), the single most effective NTD prevention. ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov

17. Guided Mindfulness Meditation. Lowers stress hormones that interfere with folate metabolism.

18. Cognitive-Behavioural Therapy (CBT). Addresses grief, guilt, or anxiety after a lethal anomaly diagnosis, reducing the risk of postpartum depression.

19. Peer-support Groups. Normalise emotional reactions and share coping strategies.

20. Smoking-cessation Coaching. Tobacco diminishes folate bioavailability and doubles NTD odds; counselling boosts quit success.

21. Nutrition Workshops. Focus on natural folate sources (dark-green vegetables, citrus, legumes) plus B-12 and choline.

22. Sleep-hygiene Training. Good sleep maintains insulin sensitivity and healthy weight—both tied to NTD risk.

23. Digital Reminders for Supplement Adherence. App-based nudges sustain folic-acid compliance through the critical first 28 embryonic days.

24. Culturally-tailored Pre-pregnancy Planning Sessions. Adapt risk-reduction messages to local diet and beliefs.

25. Mindful Birthing Programs. Teach breathing and visualisation that lessen labour pain and reduce epidural requests when a palliative delivery is planned.

C. Specialised Supportive Therapies

26. Grief-oriented Music Therapy. Activates limbic circuits that modulate mood and facilitate emotional processing.

27. Palliative Care Team Consults. Clarifies goals—whether comfort care or experimental fetal repair—thus reducing decisional regret.

28. Chaplaincy or Spiritual Counselling. Supports families whose belief systems guide pregnancy-termination decisions.

29. Genetic-counselling Follow-up. Reviews recurrence risk and offers plan for high-dose folate in future pregnancies.

30. Environmental Risk-audit Home Visits. Identify mycotoxins, pesticides, or heavy metals that might compromise one-carbon metabolism and escalate NTD risk.

Evidence-Based Drug Interventions

Because the fetus cannot be cured after full craniorachischisis develops, most pharmacology targets prevention or maternal wellbeing. Typical adult dosing and major side-effects are noted; always individualise under medical guidance.

1. Folic Acid 4 mg PO daily. Class: water-soluble B-vitamin. Timing: ≥1 month pre-conception through 12 weeks gestation. SE: mild nausea. ncbi.nlm.nih.gov

2. Levomefolate Calcium 1 mg PO daily. Activated folate for parents with MTHFR polymorphisms; bypasses enzyme block.

3. Vitamin B-12 (Cyanocobalamin) 1000 μg IM monthly. Corrects hidden B-12 deficiency that masks folate lack.

4. Myo-Inositol 1 g PO BID. Class: insulin-sensitiser; shows additive NTD risk reduction in small trials.

5. Metformin 500 mg PO BID. Improves glycaemic control when diet alone fails; hyperglycaemia is teratogenic.

6. Acarbose 50 mg PO TID with meals. Post-prandial glucose blunting without systemic hypoglycaemia.

7. Levothyroxine (dose weight-adjusted). Treats maternal hypothyroidism, a recognised NTD co-factor.

8. Omega-3 Fish-oil Capsules 1 g/day. Modulates prostaglandins and may support neuronal membrane integrity.

9. Choline 550 mg/day. Methyl-donor synergistic with folate.

10. L-Methylfolate (medical food) 7.5 mg/day when conventional folic acid intolerance occurs.

11. Pregnancy-safe Multivitamin (contains Zn, Fe, B-complex). Broad micronutrient coverage.

12. Ondansetron ODT 4 mg PRN. Controls hyperemesis gravidarum to maintain supplement intake; rare QT prolongation.

13. Acetaminophen ≤3 g/day. Analgesia without NSAID fetal-circulation effects.

14. Low-dose Aspirin 81 mg nightly from 12 weeks. Reduces pre-eclampsia risk, indirectly enhancing placental folate flow.

15. Controlled-release Iron (Ferrous bisglycinate) 18–27 mg elemental daily. Corrects anaemia, improving oxygenation.

16. Levetiracetam 500 mg BID (if antiseizure drug needed; lower NTD risk than valproate).

17. Folinic Acid “Rescue” 15 mg PO weekly for parents who must stay on methotrexate-like medications (rare).

18. Docusate 100 mg BID. Prevents constipation escalating maternal straining injuries.

19. Magnesium Oxide 400 mg QHS. Smooth-muscle relaxant; eases cramps that limit activity.

20. Probiotic Capsules (≥10 ^9 CFU Lactobacillus). Gut-flora modulation enhances folate absorption.

Dietary Molecular Supplements

1. 5-MTHF Powder (400–800 µg/day). Bypasses MTHFR; donates methyl groups for DNA synthesis.

2. Choline Bitartrate (550–650 mg/day). Vital for phosphatidylcholine in neural membranes.

3. DHA Algal Oil (200–300 mg/day). Builds cortical neuron lipid rafts; anti-inflammatory.

4. L-Arginine (3 g/day). NO precursor improving placental perfusion.

5. Zinc Gluconate (11–13 mg/day). Cofactor for folate enzymes.

6. Riboflavin (1.4 mg/day). Supports homocysteine remethylation.

7. Betain (Trimethylglycine) 1 g/day. Alternative methyl donor when folate is low.

8. N-Acetylcysteine 600 mg/day. Antioxidant guarding neural folds from oxidative damage.

9. S-Adenosyl-Methionine (SAMe) 400 mg/day. Universal methyl donor, mood stabiliser.

10. Lutein 6 mg/day. Carotenoid that scavenges free radicals in rapidly dividing embryonic tissue.

Advanced / Special-class Drugs

(Investigational or off-label; use only in structured trials.)

1. Etidronate 5 mg/kg PO cyclic—a bisphosphonate studied for preventing osteoporosis in wheelchair-bound NTD survivors.

2. Zoledronic Acid 5 mg IV yearly. Potent bone-density preservation where immobilisation is lifelong.

3. BMP-7 (Osteogenic Protein-1) Injectable. Regenerative factor explored for closing osseous spinal defects.

4. Recombinant FGF-2 Gel. Promotes dural closure in experimental fetal models.

5. Autologous Amniotic-fluid Stem-cell Therapy. Early research on regenerating neuroepithelium.

6. Umbilical-cord Mesenchymal Stem Cells IV Infusion. Aims to curb inflammation and support neural repair.

7. Hyaluronic-acid Viscosupplement 2 ml intra-articular. Reduces knee pain in wheelchair athletes.

8. Platelet-rich Plasma (PRP) Epidural Injection. Investigated for chronic neuropathic pain in spina-bifida survivors.

9. Collagen Matrix Hydrogel. Scaffold for experimental fetal patch repair.

10. Magnesium-enhanced Hydroxyapatite Putty. Orthopaedic filler closing spinal lamina gaps.

Surgical Procedures

1. Open Maternal–Fetal Repair (MOMS protocol). Laparotomy and hysterotomy expose fetus at 22–25 weeks; neurosurgeons close the exposed spinal cord. Benefits: lowers hind-brain herniation, improves motor outcome in spina bifida. pubmed.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.govsciencedirect.com

2. Fetoscopic Single-Port Repair. Minimally invasive, CO₂-insufflated; reduces maternal morbidity.

3. Ex-utero Intrapartum Treatment (EXIT). Partial delivery keeps placental circulation while airway secured or neural tube dressed.

4. Elective Caesarean Section. Prevents mechanical trauma to exposed neural tissue during vaginal birth.

5. Neonatal Dural Patch Closure. Rarely used in borderline cranial defects to reduce CSF loss.

6. Ventriculoperitoneal Shunt Placement. Manages hydrocephalus if brainstem structures are partially present.

7. Orthopaedic Clubfoot Release. Improves positioning for survivors of less-extensive NTD variants.

8. Spine Stabilisation with Rods. Corrects severe scoliosis that impairs sitting balance.

9. Bladder Augmentation Surgery. Expands capacity, preventing renal damage.

10. Selective Dorsal Rhizotomy. Reduces spasticity enabling easier caregiving.

Proven Prevention Strategies

1. Begin folic-acid 0.4 mg daily at least one month before conception (4 mg if prior NTD). ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov

2. Keep fasting glucose <95 mg/dL; optimise HbA1c below 6.5 %.

3. Maintain healthy BMI (18.5–24.9); obesity doubles NTD risk.

4. Stop valproate, carbamazepine or methotrexate well before pregnancy; switch to lower-risk drugs.

5. Avoid hot tubs >39 °C in first trimester; hyperthermia disrupts neural closure.

6. Take vitamin B-12 if vegan or if serum level <300 pg/ml.

7. Stop smoking and limit alcohol; both impair folate metabolism.

8. Space pregnancies at least 12 months to replenish micronutrients.

9. Test thyroid; treat overt hypo- or hyper-thyroidism.

10. Seek genetic counselling if first-degree relative had an NTD.

When Should You See a Doctor?

• Pre-pregnancy: to start folate early, review medications, and screen for diabetes or thyroid disease.

• Positive pregnancy test: confirm gestational age and adjust folate dose.

• First-trimester ultrasound: detect NTD early (as early as 11–13 weeks).

• After abnormal scan: urgent referral to maternal–fetal-medicine and genetics.

• Persistent severe nausea: to prevent micronutrient depletion.

• Fever ≥38 °C in first trimester: prompt antipyretic advice to limit hyperthermia risk.

• Frequent smoking/alcohol slips: for cessation aids.

• Any seizure activity: AED optimisation.

• Intense grief or suicidal thoughts: mental-health review.

• Planning subsequent pregnancy: high-dose folate protocol.

What to Do & What to Avoid

1. Do build a folate-rich diet; avoid fad diets cutting leafy greens.

2. Do keep prenatal visits; avoid skipped supplement doses.

3. Do manage blood sugar; avoid sugary drinks.

4. Do moderate exercise; avoid overheating workouts.

5. Do use acetaminophen for fever; avoid NSAIDs in first trimester.

6. Do practise mindfulness; avoid unfiltered stress.

7. Do ask about safer antiseizure meds; avoid self-adjusting doses.

8. Do check for hidden folate antagonists (e.g., trimethoprim); avoid unprescribed antibiotics.

9. Do seek peer support; avoid isolation.

10. Do plan future pregnancies with your care team; avoid accidental conceptions without folate build-up.

Frequently Asked Questions

1. Can a baby survive craniorachischisis totalis?
No. The defect is incompatible with sustained life because the entire brain and spinal cord are exposed and malformed. pmc.ncbi.nlm.nih.govruralneuropractice.com

2. Is it the same as spina bifida?
It is an extreme end of the spina-bifida spectrum, combining total spina bifida with anencephaly.

3. What causes it?
Multifactorial: inadequate folate, genetic variants (MTHFR), hyperglycaemia, obesity, high fever, and some medications.

4. Will high-dose folic acid always prevent it?
Not always, but it can cut overall NTD risk by up to 70 %.

5. How early is it seen on ultrasound?
Often by 11–13 weeks via first-trimester NT scan; confirmed with detailed 18–20-week anatomy scan.

6. Does in-utero surgery work?
Open fetal repair has improved outcomes for myelomeningocele, but true craniorachischisis remains beyond current repair limits. pubmed.ncbi.nlm.nih.govsciencedirect.com

7. If the fetus cannot live, why offer physiotherapy?
Therapies focus on maternal comfort, mental health, and optimising future fertility.

8. Can folate fortification in food replace supplements?
Fortified flour helps, but individual supplements are still advised because accidental pregnancies happen.

9. Is folic acid safe at 4 mg?
Yes; excess is excreted in urine. Very high chronic doses may mask B-12 deficiency, so B-12 should be checked.

10. How soon can I try to conceive again after a craniorachischisis-affected pregnancy?
Once folate stores are replenished (≥3 months), and emotional/physical recovery is complete.

11. Will genetic testing show if I carry a risk gene?
Panels can detect some folate-pathway variants, but risk assessment remains probabilistic.

12. Are there natural supplements besides folate?
Choline, inositol, and DHA have supportive data, but none replace folate.

13. Do vaccines influence NTD risk?
No; vaccines do not raise NTD rates and may prevent high-fever illnesses that do.

14. Can men take folate to help?
Yes; paternal folate status influences sperm DNA methylation and may impact NTD risk.

15. Where can I get help after a fatal diagnosis?
Perinatal hospice programs, genetic counsellors, and peer networks such as NTD-Families United provide comprehensive support.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: June 22, 2025.